Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Purple Biotech Ltd. - American Depositary Shares (NQ:PPBT)

0.8161 -0.0039 (-0.48%)
Streaming Delayed Price Updated: 1:53 PM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Purple Biotech Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket ↗
Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dipped 37.1% to $0.1599 in pre-market trading. Here are some... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
It's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning! 
Via InvestorPlace
News headline image
Purple Biotech: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
Purple Biotech: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Purple Biotech Fortifies NT219 Patent Protection
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Announces Closing of $5 Million Registered Direct Offering
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Purple Biotech Announces $5 Million Registered Direct Offering
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Reports Second Quarter 2023 Financial Results
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 27 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  During Thursday, 56 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  On Tuesday, 56 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday morning, 70 companies achieved new lows for the year. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023 ↗
 
Via Benzinga
News headline image
Why ImmuCell Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗
Gainers Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) shares surged 131.6% to $4.03 in pre-market trading after gaining 15% on Tuesday. 
Via Benzinga
News headline image
Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Debuts Scientific Advisory Board
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.